<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295060</url>
  </required_header>
  <id_info>
    <org_study_id>EN3332-301</org_study_id>
    <nct_id>NCT01295060</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly</brief_title>
  <official_title>PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide&#xD;
      Implant in patients that were previously treated with an Octreotide implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation on the long-term safety and tolerability, including local tolerability of the&#xD;
      implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had&#xD;
      been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study&#xD;
      IP107-001.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Program was terminated for business reasons&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety and tolerability of the Octreotide Implant</measure>
    <time_frame>every 3 months for up to 2 years</time_frame>
    <description>Subjects will be assessed every 3 months via adverse event reporting and examination of the implantation site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the long term efficacy of the Octreotide Implant</measure>
    <time_frame>every 3 months for up to 2 years</time_frame>
    <description>Patients will have GH and IGF-1 analyzed every 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Octreotide Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>84 mg Octreotide Implant</description>
    <arm_group_label>Octreotide Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in the Extension Phase of Study IP107-001 and received at least one&#xD;
             84-mg octreotide hydrogel implant prior to enrollment OR previously enrolled in the&#xD;
             Extension Phase of Study IP107-001 and currently taking lanreotide or octreotide.&#xD;
&#xD;
          -  Subjects who have been successfully treated with the 84-mg octreotide hydrogel implant&#xD;
             in Study IP107 001.&#xD;
&#xD;
          -  In the opinion of the Investigator; subject has no unstable chronic medical conditions&#xD;
             and no clinically significant findings that would preclude subject's participation in&#xD;
             the study.&#xD;
&#xD;
          -  Subjects must be able to communicate, provide and sign written informed consent, and&#xD;
             be willing to participate and comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pituitary surgery less than 3 months prior to enrollment into this study&#xD;
&#xD;
          -  Liver disease (eg, cirrhosis, chronic active or persistent hepatitis or persistent&#xD;
             abnormalities of ALT, AST [level &gt;2× normal] or direct bilirubin [level &gt;1.5× normal])&#xD;
&#xD;
          -  Unstable angina, sustained ventricular arrhythmias or heart failure (NYHA III and IV)&#xD;
&#xD;
          -  Acute myocardial infarction within 3 months of Screening&#xD;
&#xD;
          -  Uncontrolled diabetes defined as having an HbA1c ≥9%&#xD;
&#xD;
          -  Symptomatic cholelithiasis&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Received any investigational drug or participated in another clinical trial except for&#xD;
             study IP107 001 within 30 days of enrollment into this study&#xD;
&#xD;
          -  Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any&#xD;
             time prior to enrollment into this study&#xD;
&#xD;
          -  Receiving pegvisomant, dopamine agonist or other therapy in combination with&#xD;
             somatostatin to control GH or IGF-1 levels prior to enrollment into this study&#xD;
&#xD;
          -  History or presence of significant cardiovascular, hepatic, renal, hematologic,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric&#xD;
             disease, any other severe coexisting or, terminal systemic disease that limits life&#xD;
             expectancy, or may interfere with the conduct of the study, or subjects who are&#xD;
             incarcerated in penal institutions or are committed to mental institutions&#xD;
&#xD;
          -  Women who are pregnant or lactating. For females of childbearing potential, a positive&#xD;
             pregnancy test prior to enrollment, or an unwillingness to use accepted forms of&#xD;
             reliable birth control for study duration (including bilateral tubal ligation, use of&#xD;
             oral contraceptives, double barrier methods [diaphragm with spermicidal gel or condoms&#xD;
             with contraceptive foam], Depo-Provera®, hormonal implants, partner vasectomy, and&#xD;
             total abstinence). Pregnancy tests are not required (indicate &quot;n/a&quot;) for males, or for&#xD;
             females not of childbearing potential (post-menopausal with last menstrual period &gt;1&#xD;
             year ago or total hysterectomy with bilateral oophorectomy)&#xD;
&#xD;
          -  An unwillingness on the part of a male subject to abstain from sexual intercourse with&#xD;
             pregnant or lactating women or an unwillingness to use a condom and spermicide and&#xD;
             another form of contraception (eg, IUD, birth control pills taken by female partner,&#xD;
             diaphragm with spermicide) if engaging in sexual intercourse with a woman who could&#xD;
             become pregnant until discharge from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <disposition_first_submitted>September 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 20, 2013</disposition_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Octreotide</keyword>
  <keyword>IGF-1</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Implant</keyword>
  <keyword>Hydrogel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

